These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 29783391)

  • 41. Early changes of plasma lipids during treatment with atypical antipsychotics.
    Rettenbacher MA; Ebenbichler C; Hofer A; Kemmler G; Baumgartner S; Edlinger M; Hummer M; Lechleitner M; Fleischhacker WW
    Int Clin Psychopharmacol; 2006 Nov; 21(6):369-72. PubMed ID: 17012984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients.
    Echeverria P; Guardiola M; González M; Vallvé JC; Bonjoch A; Puig J; Clotet B; Ribalta J; Negredo E
    Antiviral Res; 2015 Feb; 114():48-52. PubMed ID: 25500319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of the APOC3 Sst I SNP on fasting triglyceride levels in men heterozygous for the LPL P207L deficiency.
    Garenc C; Couillard C; Laflamme N; Cadelis F; Gagné C; Couture P; Julien P; Bergeron J
    Eur J Hum Genet; 2005 Oct; 13(10):1159-65. PubMed ID: 16015281
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation.
    Dietrich-Muszalska A; Rabe-Jablonska J; Nowak P; Kontek B
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):268-75. PubMed ID: 20218792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
    Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
    Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study.
    Hallman DM; Srinivasan SR; Chen W; Boerwinkle E; Berenson GS
    Metabolism; 2006 Dec; 55(12):1574-81. PubMed ID: 17142127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.
    Hong CJ; Chen TT; Bai YM; Liou YJ; Tsai SJ
    World J Biol Psychiatry; 2012 Jan; 13(1):22-9. PubMed ID: 21375366
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
    Arnedo M; Taffé P; Sahli R; Furrer H; Hirschel B; Elzi L; Weber R; Vernazza P; Bernasconi E; Darioli R; Bergmann S; Beckmann JS; Telenti A; Tarr PE;
    Pharmacogenet Genomics; 2007 Sep; 17(9):755-64. PubMed ID: 17700364
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of genetic risk for dyslipidemia.
    Yamada Y; Matsuo H; Warita S; Watanabe S; Kato K; Oguri M; Yokoi K; Metoki N; Yoshida H; Satoh K; Ichihara S; Aoyagi Y; Yasunaga A; Park H; Tanaka M; Nozawa Y
    Genomics; 2007 Nov; 90(5):551-8. PubMed ID: 17919884
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic variation and antipsychotic drug effects on serum lipids.
    Hallman DM
    Per Med; 2008 Jan; 5(1):77-81. PubMed ID: 29783391
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Pharmacogenetics and tailored drug treatment in schizophrenia].
    Andreassen OA; Steen VM
    Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2400-2. PubMed ID: 16998555
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.